Cmed Technology adds more capabilities to its encapsia platform and reports increased demand for use

Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity.
By: Scott PR
 
HORSHAM, U.K. - June 2, 2021 - PRLog -- Cmed Technology has today announced increased capabilities for encapsia, its advanced enterprise, cloud-based clinical data system, after increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI.

Cmed Technology prioritizes enhancements through alignment of client feedback with strategic and environmental changes to the marketplace (e.g., the pandemic). Our project managers and technical consultants operate collaboratively with the client operational teams, holding regular deep-dive governance meetings to support the goals of our clients at both tactical and strategic level.

As biotechnology, pharmaceutical, and medical device companies resumed clinical development in 2020, the new reality necessitated solutions to make managing, interpreting, visualizing, and analyzing data from their clinical programs simpler. This required augmenting and automating clinical research processes to facilitate these decentralized, virtualized, and hybrid trials. Since Q4 2020, Cmed has seen a rapid uptake of the encapsia platform, particularly eSource, by sponsors conducting everything from phase I to large scale phase IV studies.

Some of the latest encapsia enhancements include:
  • Ability to add images and files into encapsia EDC – providing evidence to facilitate remote monitoring. Sites use any mobile phone (Android or iOS) to capture images and redact as necessary before upload.
  • EDC supports complex client specific data entry options, together with reports and visualizations directly within the eCRF.
  • Drug supply management and randomization is included through hyper-integration with Endpoint Clinical (and other randomization and supply vendors) to offer seamless logistic supply management and randomization to sites.
  • Ability of a user to 'pin' their favorite reports/visualizations for immediate access wherever they are in encapsia.
  • Greater options for clients collecting eSource data – more configurable elements, patient mode, and enhanced queries options.
  • New home visit option e.g., for DCT (study nurses visiting patients in their homes).
Dr Timothy Corbett-Clark, Chief Technology Officer, Cmed Technology, commented: "The promise of encapsia is to bring the tech to the data, remove product boundaries, and deliver a holistic, fit for purpose solution that can support the entire development lifecycle. As more data of more types are gleaned from more sources, it all needs to come together for real-time processing during study conduct. That's what our clients are asking for, and it requires a revolutionary eClinical platform built with the future of clinical research in mind."

For more information, please visit https://encapsia.com/.

Contact
Lucy Shaw
***@scottpr.com
End
Email:***@scottpr.com Email Verified
Tags:Clinical Trials
Industry:Research
Location:Horsham - West Sussex - England
Subject:Features
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
The Scott Partnership PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share